JP2012521215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521215A5 JP2012521215A5 JP2012501965A JP2012501965A JP2012521215A5 JP 2012521215 A5 JP2012521215 A5 JP 2012521215A5 JP 2012501965 A JP2012501965 A JP 2012501965A JP 2012501965 A JP2012501965 A JP 2012501965A JP 2012521215 A5 JP2012521215 A5 JP 2012521215A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- phenotype
- cell
- suspension
- nkt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000822 natural killer cell Anatomy 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 14
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 12
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 12
- 210000000581 natural killer T-cell Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 239000000725 suspension Substances 0.000 claims 4
- 102000000588 Interleukin-2 Human genes 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 239000006285 cell suspension Substances 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 3
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000263 cytotoxicity test Toxicity 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000012467 final product Substances 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16359009P | 2009-03-26 | 2009-03-26 | |
| US61/163,590 | 2009-03-26 | ||
| PCT/SE2010/050333 WO2010110734A1 (en) | 2009-03-26 | 2010-03-25 | Expansion of nk cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015254493A Division JP2016105713A (ja) | 2009-03-26 | 2015-12-25 | Ｎｋ細胞の増殖 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012521215A JP2012521215A (ja) | 2012-09-13 |
| JP2012521215A5 true JP2012521215A5 (enExample) | 2013-04-25 |
Family
ID=42781254
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012501965A Pending JP2012521215A (ja) | 2009-03-26 | 2010-03-25 | Ｎｋ細胞の増殖 |
| JP2015254493A Pending JP2016105713A (ja) | 2009-03-26 | 2015-12-25 | Ｎｋ細胞の増殖 |
| JP2017208238A Active JP6574823B2 (ja) | 2009-03-26 | 2017-10-27 | Ｎｋ細胞の増殖 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015254493A Pending JP2016105713A (ja) | 2009-03-26 | 2015-12-25 | Ｎｋ細胞の増殖 |
| JP2017208238A Active JP6574823B2 (ja) | 2009-03-26 | 2017-10-27 | Ｎｋ細胞の増殖 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8877182B2 (enExample) |
| EP (1) | EP2411507B1 (enExample) |
| JP (3) | JP2012521215A (enExample) |
| KR (1) | KR101881520B1 (enExample) |
| CN (1) | CN102428173B (enExample) |
| DK (1) | DK2411507T3 (enExample) |
| ES (1) | ES2763169T3 (enExample) |
| PL (1) | PL2411507T3 (enExample) |
| PT (1) | PT2411507T (enExample) |
| WO (1) | WO2010110734A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008307633C1 (en) | 2007-09-28 | 2015-04-30 | Celularity Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| WO2012009422A1 (en) | 2010-07-13 | 2012-01-19 | Anthrogenesis Corporation | Methods of generating natural killer cells |
| JP5572863B2 (ja) * | 2011-06-24 | 2014-08-20 | 国立大学法人九州大学 | Ｎｋ細胞の増幅方法 |
| CN104204194B (zh) * | 2011-12-22 | 2018-08-03 | 财团法人牧岩生命工学研究所 | 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物 |
| US10066207B2 (en) | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| KR101525199B1 (ko) * | 2012-09-13 | 2015-06-04 | (주)케이셀바이오 | 100㎖ 이하 말초혈액으로부터 ｎｋ세포의 대량 증식 방법 |
| CN102994449A (zh) * | 2012-12-13 | 2013-03-27 | 上海柯莱逊生物技术有限公司 | 一种体外扩增nk细胞的方法 |
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| WO2014123879A1 (en) | 2013-02-05 | 2014-08-14 | Anthrogenesis Corporation | Natural killer cells from placenta |
| WO2014155572A1 (ja) * | 2013-03-27 | 2014-10-02 | 株式会社日本バイオセラピー研究所 | Nk細胞強化型血液製剤の製造方法 |
| US10260038B2 (en) | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| WO2015125113A1 (en) * | 2014-02-21 | 2015-08-27 | Dr. Reddy's Laboratories Limited | Method of culturing high cell density pbmc's |
| CN105002139B (zh) * | 2014-04-25 | 2019-02-01 | 中国医学科学院肿瘤医院 | 一种cd3+cd8+cd56+t细胞亚型促进nk细胞增殖的方法 |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| CN104357390B (zh) * | 2014-10-15 | 2017-07-07 | 恒瑞源正（深圳）生物科技有限公司 | 同时扩增cd3+cd56+cik细胞和cd3‑cd56+nk细胞的方法 |
| KR101697473B1 (ko) | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
| WO2017070237A1 (en) * | 2015-10-19 | 2017-04-27 | University Of Maryland, Baltimore | Methods for generating engineered human primary blood dendritic cell lines |
| CN105624109B (zh) * | 2016-02-26 | 2019-07-12 | 广州赛莱拉干细胞科技股份有限公司 | 一种使用生物反应器培养nkt细胞的方法 |
| CN107779434A (zh) * | 2016-08-30 | 2018-03-09 | 天津市康婷生物工程有限公司 | 高效扩增人外周血nk细胞的实验方法 |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| SG11201908492PA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| EP3601537A4 (en) | 2017-03-27 | 2021-01-13 | National University of Singapore | STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS |
| CN110662834B (zh) | 2017-05-26 | 2023-09-12 | Gc细胞治疗 | 使用转化的t细胞培养自然杀伤细胞的方法 |
| CN107541491A (zh) * | 2017-10-12 | 2018-01-05 | 广州金晟生物科技有限公司 | 一种nk细胞体外培养方法 |
| KR102265437B1 (ko) | 2017-11-24 | 2021-06-15 | 의료법인 성광의료재단 | Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법 |
| CN108060130B (zh) * | 2017-12-29 | 2018-12-07 | 广州沙艾生物科技有限公司 | 控制培养箱适于免疫细胞的诱导扩增的方法 |
| CN108192868B (zh) * | 2017-12-29 | 2018-12-07 | 广州沙艾生物科技有限公司 | 免疫细胞的诱导扩增方法 |
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| EP3765519B1 (en) * | 2018-03-13 | 2024-01-17 | Fundación para la Investigación Biomédica del Hospital Universitario la Paz | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
| WO2019182392A1 (ko) * | 2018-03-23 | 2019-09-26 | 주식회사 녹십자랩셀 | 자연살해세포의 제조방법 |
| KR102232321B1 (ko) * | 2018-03-23 | 2021-03-26 | 주식회사 녹십자랩셀 | 자연살해세포의 제조방법 |
| KR20200138741A (ko) | 2018-04-02 | 2020-12-10 | 내셔널 유니버시티 오브 싱가포르 | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 |
| GB201807050D0 (en) | 2018-04-30 | 2018-06-13 | Cellprotect Nordic Pharmaceuticals Ab | Medical uses |
| KR102069704B1 (ko) * | 2018-05-16 | 2020-01-23 | 고려대학교 산학협력단 | Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법 |
| KR102213108B1 (ko) * | 2018-05-31 | 2021-02-05 | 고려대학교 산학협력단 | Igfbp2를 이용한 사람 유래 자연살해세포의 확장배양 |
| CN110628715B (zh) * | 2018-06-21 | 2022-11-25 | 精准生技股份有限公司 | 体外扩增自然杀手细胞及自然杀手t细胞的方法及其医药组成物 |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| EP3892721A4 (en) | 2018-11-14 | 2022-08-31 | GC Cell Corporation | METHOD FOR CULTIVATING NATURAL KILLER CELLS DERIVED FROM UMBILICAL CORD BLOOD USING TRANSFORMED T LYMPHOCYTES |
| CN113891934A (zh) * | 2018-11-21 | 2022-01-04 | 因达普塔治疗公司 | 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| SG11202110261QA (en) * | 2019-03-21 | 2021-10-28 | Gamida Cell Ltd | Expanded nk cell fractions for transplantation in combination therapy |
| US11453862B2 (en) | 2019-07-08 | 2022-09-27 | Immunitybio, Inc. | Mononuclear cell derived NK cells |
| CN113166726A (zh) * | 2019-07-08 | 2021-07-23 | 南克维斯特公司 | 单核细胞源性nk细胞 |
| WO2021154886A1 (en) | 2020-01-28 | 2021-08-05 | Sorrento Therapeutics, Inc. | Natural killer cells for treatment of coronavirus infection |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| US20240307536A1 (en) * | 2021-01-12 | 2024-09-19 | Hadasit Medical Research Services And Development Ltd. | Improved adoptive cell transfer therapy for cancer |
| GB202115389D0 (en) | 2021-10-26 | 2021-12-08 | XNK Therapeutics AB | Methods |
| WO2023081813A1 (en) | 2021-11-05 | 2023-05-11 | St. Jude Children's Research Hospital, Inc. | Zip cytokine receptors |
| EP4536687A1 (en) | 2022-06-08 | 2025-04-16 | St. Jude Children's Research Hospital, Inc. | Disruption of kdm4a in t cells to enhance immunotherapy |
| WO2024059787A1 (en) | 2022-09-16 | 2024-03-21 | St. Jude Children's Research Hospital, Inc. | Disruption of asxl1 in t cells to enhance immunotherapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2425801A (en) | 1999-11-24 | 2001-06-04 | Ernest G. Hope | Anti-angiogenic cellular agent for cancer therapy |
| US20030119185A1 (en) * | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| KR20030032961A (ko) * | 2000-06-06 | 2003-04-26 | 기린 비루 가부시키가이샤 | 내츄럴 킬러 ｔ 세포의 증폭 방법 |
| US20030068306A1 (en) * | 2001-09-14 | 2003-04-10 | Dilber Mehmet Sirac | Medium |
| BRPI0510886A (pt) * | 2004-06-18 | 2007-12-26 | Genentech Inc | método para aumentar a apoptose ou a citotoxicidade em células de mamìferos |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| KR101299299B1 (ko) * | 2007-11-05 | 2013-08-26 | 츠네오 쿠라모치 | 암면역 요법용 세포의 제조방법 |
| US20090123442A1 (en) * | 2007-11-09 | 2009-05-14 | Avaris Ab | Expanded nk cells |
| KR20090127974A (ko) * | 2008-06-10 | 2009-12-15 | 주식회사 엔케이바이오 | 자기활성화 림프구 배양용 배지 조성물 |
-
2010
- 2010-03-25 JP JP2012501965A patent/JP2012521215A/ja active Pending
- 2010-03-25 EP EP10756430.4A patent/EP2411507B1/en active Active
- 2010-03-25 PL PL10756430T patent/PL2411507T3/pl unknown
- 2010-03-25 DK DK10756430.4T patent/DK2411507T3/da active
- 2010-03-25 US US13/260,004 patent/US8877182B2/en active Active
- 2010-03-25 KR KR1020117025234A patent/KR101881520B1/ko active Active
- 2010-03-25 ES ES10756430T patent/ES2763169T3/es active Active
- 2010-03-25 PT PT107564304T patent/PT2411507T/pt unknown
- 2010-03-25 CN CN201080021237.8A patent/CN102428173B/zh active Active
- 2010-03-25 WO PCT/SE2010/050333 patent/WO2010110734A1/en not_active Ceased
-
2015
- 2015-12-25 JP JP2015254493A patent/JP2016105713A/ja active Pending
-
2017
- 2017-10-27 JP JP2017208238A patent/JP6574823B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012521215A5 (enExample) | ||
| JP7242761B2 (ja) | キメラ抗原受容体及び他の受容体の発現に対するｔ細胞 | |
| Peters et al. | Ex vivo generation of human alloantigen-specific regulatory T cells from CD4posCD25high T cells for immunotherapy | |
| CN108473959B (zh) | 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法 | |
| KR101963920B1 (ko) | Nk 세포의 증폭 방법 | |
| CN104321425B (zh) | 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法 | |
| CN102428173B (zh) | Nk细胞的扩增 | |
| JP2016509840A5 (enExample) | ||
| CN107002039B (zh) | 使用t细胞用于培养自然杀伤细胞的方法 | |
| TWI410495B (zh) | 新穎之人類ｔ細胞群 | |
| Bonanno et al. | Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures | |
| JP2021090459A (ja) | 心筋細胞シート | |
| TWI612137B (zh) | 含免疫細胞之組成物的製造方法及癌症治療用組成物 | |
| JP5840876B2 (ja) | Ｎｋ細胞を増幅するための組成物及び方法 | |
| Peragine et al. | Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients | |
| Davis et al. | Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation | |
| WO2001038494A1 (en) | Method of proliferating natural killer cells | |
| Gu et al. | Rapamycin together with TGF-β1, IL-2 and IL-15 induces the generation of functional regulatory γδT cells from human peripheral blood mononuclear cells | |
| JP5989016B2 (ja) | Ｎｋ細胞の増幅方法 | |
| Lee et al. | Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy | |
| KR102663157B1 (ko) | Ｔｃｒ감마 델타 양성 ｔ 세포의 생산 방법 | |
| Li et al. | Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells | |
| Iwaszkiewicz-Grzes et al. | Antigen-reactive regulatory T cells can be expanded in vitro with monocytes and anti-CD28 and anti-CD154 antibodies | |
| CN113502265A (zh) | 将t细胞重编程为类nk细胞的诱导剂及其应用 | |
| Khanal et al. | Feeder Cell-Free Production of CAR-NK Cells via Activation of PKC and Calcium Signaling Pathways |